<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10330006</article-id><article-id pub-id-type="pmcid-ver">PMC10330006.319</article-id><article-id pub-id-type="pmcaid">10330006</article-id><article-id pub-id-type="pmcaiid">10330006</article-id><article-id pub-id-type="manuscript-id">NIHMS1878289</article-id><article-id pub-id-type="pmid">36843415</article-id><article-id pub-id-type="doi">10.1111/add.16178</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1878289</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1878289</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002&#8211;2017</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Larney</surname><given-names initials="S">Sarah</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="NR">Nicola R.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hickman</surname><given-names initials="M">Matthew</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nielsen</surname><given-names initials="S">Suzanne</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ali</surname><given-names initials="R">Robert</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Degenhardt</surname><given-names initials="L">Louisa</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Centre de recherche du Centre hospitalier de l&#8217;Universit&#233; de Montr&#233;al</aff><aff id="A2"><label>2</label>Department of Family Medicine and Emergency Medicine, University of Montreal</aff><aff id="A3"><label>3</label>National Drug and Alcohol Research Centre, UNSW Sydney</aff><aff id="A4"><label>4</label>Bristol Medical School, Bristol University</aff><aff id="A5"><label>5</label>Monash Addiction Research Centre, Eastern Health Clinical School, Monash University</aff><aff id="A6"><label>6</label>Faculty of Health and Medical Sciences, University of Adelaide</aff><author-notes><fn fn-type="COI-statement" id="FN1"><p id="P53"><bold>Declarations of interests:</bold> In the past three years, LD has received investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior and Seqirus. SN has received investigator-initiated untied educational grants from Seqirus, and is a named investigator on an implementation trial funded by Indivior. SL has previously received an untied educational grant from Indivior.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2023</year></pub-date><volume>118</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">440315</issue-id><fpage>1527</fpage><lpage>1539</lpage><pub-history><event event-type="nihms-submitted"><date><day>19</day><month>03</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-01 00:25:14.000"><day>01</day><month>08</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1878289.pdf"/><abstract id="ABS1"><sec id="S1"><title>Aims:</title><p id="P1">To quantify the association between opioid agonist treatment (OAT) and overdose death by age group; test the hypothesis that across different age groups, opioid overdose mortality is lowest during OAT with buprenorphine compared with time out of treatment or OAT with methadone; and test associations between OAT and opioid overdose mortality in the presence of chronic circulatory, respiratory, liver, and kidney diseases.</p></sec><sec id="S2"><title>Design:</title><p id="P2">Retrospective observational cohort study using linked administrative data.</p></sec><sec id="S3"><title>Setting:</title><p id="P3">New South Wales, Australia.</p></sec><sec id="S4"><title>Participants:</title><p id="P4">37,764 people prescribed OAT, 1 August 2002 and 31 December 2017.</p></sec><sec id="S5"><title>Measurements:</title><p id="P5">OAT exposure, opioid overdose mortality, and key confounders were measured using linked population datasets on OAT entry and exit, hospitalisation, mental health care, incarceration, and mortality. ICD-10 codes were used to define opioid overdose mortality and chronic disease groups of interest.</p></sec><sec id="S6"><title>Findings:</title><p id="P6">Relative to time out of treatment, time in OAT was associated with lower risk of opioid overdose death across all age groups and chronic diseases. Among people aged 50 years and older, there was weak evidence that buprenorphine may be associated with greater protection against opioid overdose death than methadone (generalised estimating equation [GEE] adjusted incident rate ratio (aIRR) 0.47; 95% confidence interval (CI) 0.21, 1.02; marginal structural models [MSM] aIRR 0.49; 95%CI 0.17, 1.41). Buprenorphine was associated with greater protection against overdose death than methadone for clients with circulatory (MSM aIRR 0.27; 95% CI 0.11, 0.67) or respiratory (MSM aIRR 0.26; 95% CI 0.07, 0.94) diseases, but not liver (MSM aIRR 0.59; 95% CI 0.14, 2.43) or kidney (MSM aIRR 1.16; 95% CI 0.31, 4.36) diseases.</p></sec><sec id="S7"><title>Conclusions:</title><p id="P7">Opioid agonist treatment (OAT) appears to reduce mortality risk in people with opioid use disorder who are older or who have physical comorbidities. Opioid overdose mortality during OAT with buprenorphine appears to be lower and reduced in clients with circulatory and respiratory diseases compared with OAT with methadone.</p></sec></abstract><kwd-group><kwd>opioid agonist treatment</kwd><kwd>methadone</kwd><kwd>buprenorphine</kwd><kwd>overdose</kwd><kwd>older adults</kwd><kwd>comorbidity</kwd><kwd>multimorbidity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>